• Explore /
  • Poster
  • / Preliminary results of a factorial phase II randomized trial of continuous (c) or intermittent (i) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial).

Preliminary results of a factorial phase II randomized trial of continuous (c) or intermittent (i) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial).

Abstract Poster

Authors

null

Orazio Caffo

Santa Chiara Hospital, Trento, Italy

Orazio Caffo , Giovanni Lo Re , Teodoro Sava , Sebastiano Buti , Cosimo Sacco , Umberto Basso , Fable Zustovich , Thomas Martini , Alessandra Perin , Antonello Veccia , Lucianna Russo , Gaetano Facchini , Carmen Barile , Angela Gernone , Rocco De Vivo , Giovanni L. Pappagallo , Enzo Galligioni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

EUDRACT 2006-005728-17

Citation

J Clin Oncol 30, 2012 (suppl 5; abstr 220)

DOI

10.1200/jco.2012.30.5_suppl.220

Abstract #

220

Poster Bd #

C21

Abstract Disclosures

Similar Posters

First Author: Orazio Caffo

Poster

2023 ASCO Annual Meeting

Selection biases in the systematic collection of breast biobank specimens.

Selection biases in the systematic collection of breast biobank specimens.

First Author: Yael Bar

First Author: Joyce M. van Dodewaard-de Jong

First Author: Urban Emmenegger